Therapy News and Research

RSS

CTRC-AACR Symposium to discuss new findings from breast cancer clinical trial

More than 9,000 people from more than 90 countries will gather Dec. 8-12, 2010, at the Henry B. Gonzales Convention Center in San Antonio, Texas, for the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

2 Dec 2010

Study reveals major findings of National Cancer Registry of Spain for Gastroenteropancreatic Neuroendocrine Tumours

The National Cancer Registry of Spain for Gastroenteropancreatic Neuroendocrine Tumours (RGETNE) is the first initiative of its type in southern Europe and focuses its efforts on profiling the incidence of gastroenteropancreatic tumours, improving diagnosis and treatment efficacy, and determining the clinical profile of patients across Spain.

1 Dec 2010

Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VPRIV (velaglucerase alfa), an enzyme replacement therapy (ERT) for long-term use in pediatric and adult type 1 Gaucher disease.

1 Dec 2010

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7.

1 Dec 2010

Health, HIV and human rights

On World AIDS Day 2010, the global community is focusing attention on protecting human rights of all people affected by HIV.

1 Dec 2010

Diabetes plays a vital role in regulating brain cholesterol: Research

The brain contains more cholesterol than any other organ in the body, has to produce its own cholesterol and won't function normally if it doesn't churn out enough. Defects in cholesterol metabolism have been linked with Alzheimer's disease and other neurodegenerative conditions. Now researchers at Joslin Diabetes Center have discovered that diabetes can affect how much cholesterol the brain can make.

1 Dec 2010

SPARTAC study examines ways to limit immune system damage in HIV infection

For most people in high-income countries HIV is considered a chronic illness which can be managed with medication. But the virus still causes extensive damage to the immune system, and treatment with antiretrovirals is a lifelong commitment. Once started, usually within three to five years following infection, the course of treatment needs to be strictly followed and taken for life.

1 Dec 2010

Active surveillance improves quality of life in low-risk prostate cancer patients

In a study that compared initial treatment strategies for low-risk prostate cancer among men 65 years old, active surveillance showed higher measures on quality of life compared to an initial treatment such as radical prostatectomy, although the optimal strategy was highly dependent on individual patient preferences for surveillance or treatment, according to a study in the December 1 issue of JAMA.

1 Dec 2010

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that initial safety and efficacy data from its ongoing Phase II Study with resminostat, a pan-Histone Deacetylase (HDAC) Inhibitor, in relapsed/refractory Hodgkin Lymphoma (HL) patients after high dose chemotherapy and autologous hematopoietic stem cell transplantation will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, USA.

1 Dec 2010

New study evaluates use and safety of complementary medicine for children's asthma

Approximately 13 percent of parents turn to alternative therapies to treat their children's asthma, according to a new study from the Universit- de Montr-al. The findings, published recently in the Canadian Respiratory Journal, suggest that this trend is associated with a two-fold higher rate of poor asthma control in children.

1 Dec 2010

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

An experimental immunotherapy may someday become the newest weapon against lung cancer. Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small cell lung cancer (NSCLC) at NewYork-Presbyterian Hospital as part of an ongoing Phase III trial.

1 Dec 2010

Precision Therapeutics to present abstracts on breast cancer therapy at San Antonio Symposium

Precision Therapeutics will present two abstracts at the 33rd Annual San Antonio Breast Cancer Symposium, which will be held December 8-12, 2010 in San Antonio, Texas.

1 Dec 2010

USC purchases WaferGen SmartChip system for Molecular Pathways and Drug Discovery center

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced that the University of Southern California (USC) has purchased the WaferGen SmartChip system for its USC Center for Molecular Pathways and Drug Discovery to discover and validate biomarkers for pancreatic and colorectal cancer applications to expedite the development of a cancer therapy. USC purchased a solution that includes the SmartChip platform and validated gene panels for biomarker profiling.

1 Dec 2010

Study shows link between reduced hormone therapy and decline in breast cancer

In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.

1 Dec 2010

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Neuroscientists using a new brain imaging technique could see an investigational drug for Parkinson's disease get into a patient's brain and affect blood flow in several key structures, an indicator the drug may be effective.

1 Dec 2010

Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

New data on UCB's anti-epileptic drug (AED) Vimpat (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7, 2010. Data will also be presented on Keppra XR and the investigative epilepsy therapy, brivaracetam.

1 Dec 2010

Number of people living with HIV/AIDS in Africa to outpace treatment resources by 2020, IOM report finds

The number of people living with HIV/AIDS in Africa is projected to greatly outpace treatment resources by the end of the decade, according to a report released Monday by the Institute of Medicine (IOM), Reuters reports (Fox, 11/29).

1 Dec 2010

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Rush University Medical Center has just enrolled the first U.S. patient in an international clinical trial testing a novel drug to treat certain kinds of melanoma, a deadly skin cancer that in its advanced stages currently has few effective treatments.

1 Dec 2010

GenSpera expands G-202 Phase I safety trial to CTRC at University of Texas Health Science Center

GenSpera, Inc. announced its intention to expand its Phase I safety trial to study G-202 in relapsed, refractory cancer patients to the Cancer Therapy and Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, TX. The expansion is dependent upon a successful review of the clinical protocol by the Health Science Center Institutional Review Board (IRB). The company anticipates admitting the first patient at this site in the first quarter of 2011.

1 Dec 2010

Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV

Argos Therapeutics today announced that it has initiated dosing of patients in a Phase 2b clinical trial of its Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004.

30 Nov 2010

Therapy News and Research

CTRC-AACR Symposium to discuss new findings from breast cancer clinical trial

Study reveals major findings of National Cancer Registry of Spain for Gastroenteropancreatic Neuroendocrine Tumours

Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Health, HIV and human rights

Diabetes plays a vital role in regulating brain cholesterol: Research

SPARTAC study examines ways to limit immune system damage in HIV infection

Active surveillance improves quality of life in low-risk prostate cancer patients

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

New study evaluates use and safety of complementary medicine for children's asthma

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

Precision Therapeutics to present abstracts on breast cancer therapy at San Antonio Symposium

USC purchases WaferGen SmartChip system for Molecular Pathways and Drug Discovery center

Study shows link between reduced hormone therapy and decline in breast cancer

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

Number of people living with HIV/AIDS in Africa to outpace treatment resources by 2020, IOM report finds

Rush University enrolls first U.S. patient in international clinical trial for melanoma

GenSpera expands G-202 Phase I safety trial to CTRC at University of Texas Health Science Center

Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News